Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 8—August 2006
Research

VEB-1 Extended-Spectrum β-lactamase–producing Acinetobacter baumannii, France1

Thierry Naas*2Comments to Author , Bruno Coignard†2, Anne Carbonne‡, Karine Blanckaert‡, Odile Bajolet§, Claude Bernet¶, Xavier Verdeil#, Pascal Astagneau‡, Jean-Claude Desenclos†, Patrice Nordmann*, on behalf ofthe French Nosocomial Infection Early Warning, Investigation and Surveillance Network
Author affiliations: *Hôpital de Bicêtre, Le Kremlin-Bicêtre, France; †Institut de Veille Sanitaire, Saint-Maurice, France; ‡Centre de Coordination de Lutte contre les Infections Nosocomiales Paris Nord, Paris, France; §Réseau Bactéries Multi-Résistantes Champagne-Ardennes, Centre Hospitalier et Universitaire, Reims, France; ¶Centre de Coordination de Lutte contre les Infections Nosocomiales Sud-Est, Lyon, France; #Centre de Coordination de Lutte Contre les Infections Nosocomiales Sud-Ouest et Centre Hospitalier et Universitaire, Toulouse, France

Main Article

Table 2

Recommendations for hospitals*†

Type Recommendation
Notification Report any case of infection or colonization with Acinetobacter baumannii strain showing resistance profile similar to that of 2001 outbreak strain (16) to CCLIN and local health department; attach copy of antibiogram.
Laboratory guidelines Establish identification criteria based on antibiogram
Store strains and contact central laboratory for microbiologic investigation
Medical wards Inform all medical teams and paramedics of presence of bacterial strain
Ensure appropriate use of antimicrobial drugs in high-risk wards
Infection control team Set up systematic screening of patients in high-risk wards
Reinforce isolation protocols and standard hygiene precautions throughout hospital
Reinforce surface cleaning procedures in wards where infected or colonized patients have been
Patient transfer Limit internal and external patient transfers
Inform receiving hospitals of status of patients colonized or infected with ESBL-producing A. baumannii

*CCLIN, regional infection control coordinating centers; ESBL, extended-spectrum β-lactamase.
†At the national level, recommendations were disseminated by the National Institute of Public Health (Institut de Veille Sanitaire) and the French Nosocomial Infection Early Warning, Investigation and Surveillance Network (Réseau d'Alerte, d'Investigation et de Surveillance des Infections Nosocomiales) through its website (http://www.invs.sante.fr/raisin, "alerte" section). At the regional level, they were disseminated to all hospital laboratories and infection control units by CCLIN through email notifications and their respective websites. In each hospital, they were implemented in the wards by infection control units assisted by CCLIN, when necessary.

Main Article

References
  1. Allen  DM, Hartman  BJ. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:2339–44.
  2. Bergogne-Bérézin  E, Towner  KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev. 1996;9:148–65.PubMedGoogle Scholar
  3. Villegas  MV, Hartstein  AI. Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003;24:284–95. DOIPubMedGoogle Scholar
  4. Carbonne  A, Naas  T, Blanckaert  K, Couzigou  C, Cattoen  C, Aggoune  M, Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect. 2005;60:14–8. DOIPubMedGoogle Scholar
  5. d'Alerte  R. d'investigation et de surveillance des infections nosocomiales. Enquête nationale de prévalence 2001—Résultats. Saint-Maurice (France): Institut de Veille Sanitaire; 2003. p. 22 [cited 2005 Sep 27]. Available from http://www.invs.sante.fr/publications/2003/raisin_enp_2001/raisin_enp_2001_p_19_50.pdf
  6. Gales  AC, Jones  RN, Forward  KR, Linares  J, Sader  HS, Verhoef  J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001;32:S104–13. DOIPubMedGoogle Scholar
  7. Afzal-Shah  M, Livermore  DM. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 1998;41:576–7. DOIPubMedGoogle Scholar
  8. Nordmann  P, Poirel  L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect. 2002;8:321–31. DOIPubMedGoogle Scholar
  9. Landman  D, Quale  JM, Mayorga  D, Adedeji  A, Vangala  K, Ravishankar  J, Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. Arch Intern Med. 2002;162:1515–20. DOIPubMedGoogle Scholar
  10. Bou  G, Cerveró  G, Domínguez  MA, Quereda  C, Martínez-Beltrán  J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol. 2000;38:3299–305.PubMedGoogle Scholar
  11. Fernández-Cuenca  F, Martínez-Martínez  L, Conejo  MC, Ayala  JA, Perea  EJ, Pascual  A. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2003;51:565–74. DOIPubMedGoogle Scholar
  12. Corvec  S, Caroff  N, Espaze  E, Giraudeau  C, Drugeon  H, Reynaud  A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother. 2003;52:629–35. DOIPubMedGoogle Scholar
  13. Vahaboglu  H, Öztürk  R, Aygün  G, Coskunkan  F, Yaman  A, Kaygusuz  A, Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother. 1997;41:2265–9.PubMedGoogle Scholar
  14. Yong  D, Shin  JH, Kim  S, Lim  Y, Yum  JH, Lee  K, High prevalence of PER-1 extended-spectrum beta-lactamase–producing Acinetobacter spp. in Korea. Antimicrob Agents Chemother. 2003;47:1749–51. DOIPubMedGoogle Scholar
  15. Poirel  L, Karim  A, Mercat  A, Le Thomas  I, Vahaboglu  H, Richard  C, Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother. 1999;43:157–65. DOIPubMedGoogle Scholar
  16. Poirel  L, Menuteau  O, Agoli  N, Cattoen  C, Nordmann  P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol. 2003;41:3542–7. DOIPubMedGoogle Scholar
  17. Nagano  N, Nagano  Y, Cordevant  C, Shibata  N, Arakawa  Y. Nosocomial transmission of CTX-M-2 β-lactamase–producing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol. 2004;42:3978–84. DOIPubMedGoogle Scholar
  18. Poirel  L, Naas  T, Guibert  M, Chaibi  EB, Labia  R, Nordmann  P. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother. 1999;43:573–81.PubMedGoogle Scholar
  19. Naas  T, Mikami  Y, Imai  T, Poirel  L, Nordmann  P. Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes. J Bacteriol. 2001;183:235–49. DOIPubMedGoogle Scholar
  20. Girlich  D, Naas  T, Leelaporn  A, Poirel  L, Fennewald  M, Nordmann  P. Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum beta-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis. 2002;34:603–11. DOIPubMedGoogle Scholar
  21. Horan  TC, Gaynes  RP. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital epidemiology and infection control. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1659–702.
  22. Astagneau  P, Brucker  G. Organization of hospital-acquired infection control in France. J Hosp Infect. 2001;47:84–7. DOIPubMedGoogle Scholar
  23. Coignard  B, Lepoutre  A, Desenclos  JC. Lessons learned from implementing a mandatory notification of hospital acquired infections in France [cited June 11, 2006]. HELICS Conference; Nov 27, 2004; Lyon, France. Available from http://helics.univ-lyon1.fr/conference/6a.pdf
  24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. M100–S15. Wayne (PA): The Institute; 2005.
  25. Tenover  FC, Arbeit  RD, Goering  RV, Mickelsen  PA, Murray  BE, Persing  DH, Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–9.PubMedGoogle Scholar
  26. Carbonne  A, Blanckaert  K, Naas  T, Seringe  E, Botherel  AH, Aggoune  M, Investigation et contrôle d'une épidémie régionale à Acinetobacter baumannii producteur de bêta-lactamase à spectre étendu VEB-1, Nord—Pas de Calais, avril 2003 à février 2004. Bulletin Epidémiologique Hebdomadaire [serial online]. 2004;32–3 [cited 2005 May 5]. Available from http://www.invs.sante.fr/beh/2004/32_33/index.htm
  27. Bureau-Chalot  F, Drieux  L, Pierrat-Solans  C, Forte  D, de Champs  C, Bajolet  O. Blood pressure cuffs as potential reservoirs of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii. J Hosp Infect. 2004;58:91–2. DOIPubMedGoogle Scholar
  28. Hérìtier  C, Dubouix  A, Poirel  L, Marty  N, Nordmann  P. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother. 2005;55:115–8. DOIPubMedGoogle Scholar
  29. Shlaes  DM, Gerding  DN, John  JFJ, Craig  WA, Bornstein  DL, Duncan  RA, Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275–91. DOIPubMedGoogle Scholar
  30. Garcia-Garmendia  JL, Ortiz-Leyba  C, Garnacho-Montero  J, Jimenez-Jimenez  FJ, Monterrubio-Villar  J, Gili-Miner  M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999;27:1794–9. DOIPubMedGoogle Scholar
  31. Ostrowsky  BE, Trick  WE, Sohn  AH, Quirk  SB, Holt  S, Carson  LA, Control of vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J Med. 2001;344:1427–33. DOIPubMedGoogle Scholar
  32. van Dessel  H, Dijkshoorn  L, van der Reijden  T, Bakker  N, Paauw  A, van den Broek  P, Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol. 2004;155:105–12. DOIPubMedGoogle Scholar
  33. Marque  S, Poirel  L, Heritier  C, Brisse  S, Blasco  MD, Filip  R, Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol. 2005;43:4885–8. DOIPubMedGoogle Scholar
  34. de Vries  J, Wackernagel  W. Integration of foreign DNA during natural transformation of Acinetobacter sp. by homology-facilitated illegitimate recombination. Proc Natl Acad Sci U S A. 2002;99:2094–9. DOIPubMedGoogle Scholar
  35. Turton  JF, Kaufmann  ME, Warner  M, Coelho  J, Dijkshoorn  L, van der Reijden  T, A prevalent, multiresistant clone of Acinetobacter baumannii in southeast England. J Hosp Infect. 2004;58:170–9. DOIPubMedGoogle Scholar
  36. Dalla-Costa  LM, Coelho  JM, Souza  HA, Castro  ME, Stier  CJ, Bragagnolo  KL, Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol. 2003;41:3403–6. DOIPubMedGoogle Scholar
  37. Naas  T, Levy  M, Hirschauer  C, Marchandin  H, Nordmann  P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol. 2005;43:4826–9. DOIPubMedGoogle Scholar
  38. Jans  B, Glupczynski  Y, Suetens  C, Van Cleemput  E. Enquête épidémiologique relative à Acinetobacter baumannii producteur de BLSE (type VEB-1) en Belgique. Institut Scientifique de la Santé Publique, ISP/EPI Report No. 2004–18, Octobre 2004 [cited 2005 Sep 27]. Available from http://www.iph.fgov.be/epidemio/epinl/nsihnl/acinetobacter.pdf

Main Article

1This study was presented in part at the 2004 Annual Conference on Antimicrobial Resistance: Science • Prevention • Control, June 28–30, 2004, Bethesda, Maryland, USA.

2These authors contributed equally to this work.

Page created: December 09, 2011
Page updated: December 09, 2011
Page reviewed: December 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external